In this issue of Cancer Discovery, Adams and colleagues present the discovery of a potent PROTAC, MDM2 degrader, which activates wild-type p53 leading to cancer cell death. Importantly, in a number of in vitro and in vivo experiments, the authors show that the depletion of MDM2 by PROTAC kills p53-mutant or p53-null cancer cells. See related article by Adams et al., p. 1210 (5).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/2159-8290.CD-23-0229 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation.
Cancer Discov
May 2023
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
In this issue of Cancer Discovery, Adams and colleagues present the discovery of a potent PROTAC, MDM2 degrader, which activates wild-type p53 leading to cancer cell death. Importantly, in a number of in vitro and in vivo experiments, the authors show that the depletion of MDM2 by PROTAC kills p53-mutant or p53-null cancer cells. See related article by Adams et al.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!